The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Abstract
Combination chemotherapy regimens including irinotecan and oxaliplatin markedly improve response rate and prolong median survival over fluorouracil with leucovorin (FU/LV), and have supplanted FU/LV as the standard systemic approach for metastatic colorectal cancer. The recent availability of five active chemotherapeutic agents has doubled the median overall survival for metastatic colorectal cancer from 10 to 20 months, and though the optimal strategy for incorporation of all drugs is still unclear, current data support the use of chemotherapy doublets in first-line rather than sequential single-agent therapy. Multidrug regimens increase both response rate and the proportion of patients able to undergo potentially curative resection. In addition, as many as 20% to 30% of patients never receive second-line chemotherapy. When used as single agents, bolus and infusional FU/LV and capecitabine are similarly effective but have differing toxicity. Chemotherapy combinations that incorporate infusion of FU are less toxic and more effective than those using bolus FU dosing. Capecitabine is under study as an alternative dosing method for use in combination regimens; however, the optimal dose has not been defined and final safety and efficacy outcomes are being addressed in ongoing phase II and III investigations. Three combinations have shown excellent first-line efficacy in phase III trials—IFL with bevacizumab, FOLFOX, and FOLFIRI—but neither of these combinations is clearly superior. Sound clinical judgment must continue to guide treatment decisions while we await data regarding the optimal combination and sequence of fluorouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Self-citationKabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Self-citationVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Poon, M. A., O'Connell, M. J., Moertel, C. G., Wieand, H. S., Cullinan, S. A., Everson, L. K., Krook, J. E., Mailliard, J. A., Laurie, J. A., & Tschetter, L. K. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1407 · Cited by 887
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
Colorectal Cancer Collaborative Group (2000) · BMJ · doi:10.1136/bmj.321.7260.531 · Cited by 662
Adam, R., Avisar, E., Ariche, A., Giachetti, S., Azoulay, D., Castaing, D., Kunstlinger, F., Levi, F., & Bismuth, F. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0347-3 · Cited by 657
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 556
Cassidy, J., Tabernero, J., Twelves, C., Brunet, R., Butts, C., Conroy, T., Debraud, F., Figer, A., Grossmann, J., Sawada, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.069 · Cited by 525
Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., & Mittelman, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1559 · Cited by 450
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Buroker, T. R., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Mailliard, J. A., Schaefer, P. L., Levitt, R., Kardinal, C. G., & Gesme, D. H. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.1.14 · Cited by 311
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
姚方, & 陆星华 (2001) · doi:10.3760/cma.j.issn.1007-9742.2001.01.130 · Cited by 287
Kubota, K., Watanabe, K., Kunitoh, H., Noda, K., Ichinose, Y., Katakami, N., Sugiura, T., Kawahara, M., Yokoyama, A., Yokota, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.114 · Cited by 230
Scheithauer, W., Kornek, G. V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., Schneeweiss, B., Lang, F., Lenauer, A., & Depisch, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.016 · Cited by 174
Borner, M. M., Dietrich, D., Stupp, R., Morant, R., Honegger, H., Wernli, M., Herrmann, R., Pestalozzi, B. C., Saletti, P., Hanselmann, S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.087 · Cited by 169
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741
Delaunoit, T., Alberts, S. R., Sargent, D. J., Green, E., Goldberg, R. M., Krook, J., Fuchs, C., Ramanathan, R. K., Williamson, S. K., Morton, R. F., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi092 · Cited by 167
Self-citationGrothey, A. (2002) · Medical Entomology and Zoology · Cited by 167
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.122 · Cited by 160
Capecitabine as first-line treatment in colorectal cancer
Twelves, C. J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00415-4 · Cited by 139
Bajetta, E., Bartolomeo, M. D., Mariani, L., Cassata, A., Artale, S. A., Frustaci, S., Pinotti, G., Bonetti, A. V., Carreca, I. U., Biasco, G., et al. (2004) · Cancer · doi:10.1002/cncr.11910 · Cited by 137
Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Ryan, D. P., Clark, J. W., Kulke, M. H., Earle, C. C., Vincitore, M., Michelini, A. L., Sheehan, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3728 · Cited by 107
Borner, M., Bernhard, J., Dietrich, D., Popescu, R. A., Wernli, M., Saletti, P., Rauch, D., Herrmann, R., Koeberle, D., Honegger, H., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi047 · Cited by 106
Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA
Rougier, P. R., Raoul, J., Laethem, J. V., Peeters, M., Husseini, F., Brézault, C., Cals, L., Vedovato, J.-C., & Mueser, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3513 · Cited by 94
Fisher, G. A., Kuo, T., Cho-Phan, C. D., Halsey, J., Jambalos, C. N., Schwartz, E., Rouse, R. V., Advani, R. H., & Wakelee, H. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3514 · Cited by 89
O'Dwyer, P. J., Manola, J. B., Valone, F. H., RYAN, L. M., Hines, J., Wadler, S., Haller, D. G., Arbuck, S. G., Weiner, L. M., Mayer, R. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2413 · Cited by 88
Delaunoit, T., Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Findlay, B., Thomas, S. P., Salim, M., Schaefer, P., Stella, P. J., et al. (2004) · Cancer · doi:10.1002/cncr.20594 · Cited by 83
Self-citationTabernero, J. M., Cutsem, E. V., Sastre, J., Cervantes, A. M. R., Laethem, J. V., Humblet, Y., Soulié, P., Corretgé, S., Mueser, M., & de Gramont, A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3512 · Cited by 76
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3621 · Cited by 70
Self-citationKöhne, C.-H., Cutsem, E. V., Wils, J. A., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Anak, O., Genicot, B., & Nordlinger, B. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)91114-1 · Cited by 69
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
Zeuli, M., Nardoni, C., Pino, M. S., Gamucci, T., Gabriele, A., Ferraresi, V., Giannarelli, D., & Cognetti, F. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg360 · Cited by 63
Grothey, A. F., Büchele, T., Kroening, H., Ridwelski, K., Reichardt, P., Kretzschmar, A., Clemens, M. R., & Schmoll, H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81446-5 · Cited by 60
Tewes, M., Schleucher, N., Achterrath, W., Wilke, H., Frings, S., Seeber, S., Harstrick, A., Rustum, Y. M., & Vanhoefer, U. J. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg376 · Cited by 51
Seufferlein, T. T. W., Dittrich, C., Riemann, J., Woell, E., Herrmann, T. R. W., Lordick, F., Arnold, D., Olchowka, K., Hoehler, T., & Schmoll, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3644 · Cited by 36
Zampino, M. G., Lorizzo, K., Massacesi, C., Rizzi, A., Crispino, S., Boselli, S., Pelosi, G., Zorzino, L., Fazio, N., & de Braud, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3659 · Cited by 23
Zeuli, M., Gelibter, A. J., Nardoni, C., Gamucci, T., Gabriele, A., Pollera, C. F., Costanzo, F. D., Signorelli, C., Ferraresi, V., & Cognetti, F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3748 · Cited by 17
Tournigand, C., André, T., Chirivella, I., Figer, A., Lledo, G., Flesch, M., Lorenzo, J. R. M., Achille, E., Landi, B., & Hebbar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3565 · Cited by 12
Roberts, T. G., Goulart, B. H. L., Stallings, S., Squitieri, L. S., Chabner, B. A., Finkelstein, S. N., & Clark, J. W. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2084 · Cited by 12
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Portier, G., Elias, D., Bouche, O., Rougier, P., Bosset, J.-F., Saric, J., Belghiti, J., Piedbois, P., Guimbaud, R., Nordlinger, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8353 · Cited by 579
Global trends in colorectal cancer mortality: projections to the year 2035
Araghi, M., Soerjomataram, I., Jenkins, M., Brierley, J., Morris, E., Bray, F., & Arnold, M. (2019) · International Journal of Cancer · doi:10.1002/ijc.32055 · Cited by 556
Rubbia-Brandt, L., Giostra, E., Brezault, C., Roth, A. D., Andres, A., Audard, V., Sartoretti, P., Dousset, B., Majno, P. E., Soubrane, O., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl386 · Cited by 523
Metadata
- Authors
- Kelly, H., & Goldberg, R. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-07-10
- Volume
- 23
- Issue
- 20
- Pages
- 4553-4560
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161563098
- Cited by
- 316
- References
- 50
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.